Table 3 Comparison between survivors and non-survivors' groups
From: 4C mortality score and CT severity score among COVID-19 patients: a single center prospective study
Variable | Survivors | Non-survivors | p value |
|---|---|---|---|
n = 207 | n = 89 | ||
Age (mean ± SD) | 54.7 ± 14.5 | 65.3 ± 10.7 | 0.0001a |
< 60 | 113 (54.6%) | 27 (30.3%) | 0.0001b |
≥ 60 | 94 (45.4%) | 62 (69.7%) | |
Sex (n %) | |||
Male | 136 (65.7%) | 46 (51.7%) | 0.02b |
Female | 71 (34.3%) | 43 (48.3%) | |
Comorbidities | |||
Yes | 106 (51.2%) | 76 (85.4%) | 0.0001b |
No | 101 (48.8%) | 13(14.6%) | |
Inflammatory markers (mean ± SD) | |||
C reactive protein (mg/l) | 56.7 ± 37.7 | 85.8 ± 42.8 | 0.0001a |
Serum ferritin(µg/l) | 634.2 ± 347.2 | 881.7 ± 439.06 | 0.0001a |
D dimer(µ/ml) | 0.7 ± 1.8 | 1.4 ± 2.07 | 0.004a |
CT severity score (mean ± SD) | 11.5 ± 3.8 | 17.09 ± 5.8 | 0.0001a |
≤ 12 | 134 (64.7%) | 14 (15.7%) | 0.0001b |
> 12 | 73 (35.3%) | 75 (84.3%) | |
4C mortality score (mean ± SD) | 7.8 ± 4.06 | 13.01 ± 2.7 | 0.0001a |
≤ 8 | 117 (56.8%) | 6 (6.7%) | 0.0001b |
> 8 | 89 (43.2%) | 83 (93.3%) | |
Anti-viral (n %) | |||
HCQ and iverzine | 101 (48.8%) | 68 (76.4%) | 0.02b |
Lopinavir-ritonavir | 20 (9.7%) | 13 (14.6%) | 0.6b |
Favipiravir | 65 (31.4%) | 3 (3.4%) | 0.0001b |
Remdesivir | 65 (31.4%) | 71 (78%) | 0.0001b |
Supplemental O2, n (%) | 190 (92%) | 20 (22.4%) | 0.0001b |
NIV, n (%) | 72 (34.8%) | 50 (56.1%) | 0.0001b |
IMV, n (%) | 0 | 55 (61.8%) | |
Length of hospital stay (days) (mean ± SD) | 9.06 ± 4.2 | 8.8 ± 4.5 | 0.7a |